Protagenic Therapeutics, Inc.\new annual shareholders’ equity
2014
2015
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Protagenic Therapeutics, Inc.\new Shareholders’ Equity Growth & History (PTIX)
Protagenic Therapeutics, Inc.\new's shareholders’ equity was $2.6M for fiscal 2026.
View full Protagenic Therapeutics, Inc.\new company overviewProtagenic Therapeutics, Inc.\new annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | $2.6M | $7.6M | — |
| 2025 | 2025-03-31 | −$5.0M | — | — |
| 2024 | 2024-12-31 | −$3.3M | −$7.0M | — |
| 2023 | 2023-12-31 | $3.7M | −$3.2M | −46.97% |
| 2022 | 2022-12-31 | $6.9M | −$3.0M | −30.42% |
| 2021 | 2021-12-31 | $9.9M | $11.1M | — |
| 2020 | 2020-12-31 | −$1.1M | −$515,370 | — |
| 2019 | 2019-12-31 | −$634,366 | −$423,483 | — |
| 2018 | 2018-12-31 | −$210,883 | −$1.4M | — |
| 2017 | 2017-12-31 | $1.2M | −$1.3M | −50.78% |
| 2016 | 2016-12-31 | $2.5M | $3.1M | — |
| 2015 · Dec 31 | 2015-12-31 | −$667,216 | — | — |
| 2015 · Jun 30 | 2015-06-30 | −$497,000 | −$476,000 | — |
| 2014 | 2014-06-30 | −$21,000 | — | — |
Protagenic Therapeutics, Inc.\new quarterly shareholders’ equity
As of Jun 30, 2011
As of Sep 30, 2011
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | $1.7M | $5.7M | — |
| Q4 2026 | 2026-03-31 | $2.6M | $7.6M | — |
| Q3 2026 | 2025-12-31 | −$2.4M | $925,434 | — |
| Q2 2026 | 2025-09-30 | −$4.7M | −$2.2M | — |
| Q1 2026 | 2025-06-30 | −$4.0M | −$2.2M | — |
| Q4 2025 | 2025-03-31 | −$5.0M | −$3.2M | — |
| Q4 2024 | 2024-12-31 | −$3.3M | −$7.0M | — |
| Q3 2024 | 2024-09-30 | −$2.5M | −$6.6M | — |
| Q2 2024 | 2024-06-30 | −$1.8M | −$7.2M | — |
| Q1 2024 | 2024-03-31 | −$1.8M | −$8.2M | — |
| Q4 2023 | 2023-12-31 | $3.7M | −$3.2M | −46.97% |
| Q3 2023 | 2023-09-30 | $4.2M | −$3.2M | −43.75% |
| Q2 2023 | 2023-06-30 | $5.4M | −$2.8M | −34.44% |
| Q1 2023 | 2023-03-31 | $6.4M | −$2.3M | −26.44% |
| Q4 2022 | 2022-12-31 | $6.9M | −$3.0M | −30.42% |
| Q3 2022 | 2022-09-30 | $7.4M | $17.8M | — |
| Q2 2022 | 2022-06-30 | $8.3M | −$2.5M | −23.52% |
| Q1 2022 | 2022-03-31 | $8.7M | $10.7M | — |
| Q4 2021 | 2021-12-31 | $9.9M | $11.1M | — |
| Q3 2021 | 2021-09-30 | −$10.4M | −$9.3M | — |
| Q2 2021 | 2021-06-30 | $10.8M | $11.5M | — |
| Q1 2021 | 2021-03-31 | −$2.0M | −$1.4M | — |
| Q4 2020 | 2020-12-31 | −$1.1M | −$515,370 | — |
| Q3 2020 | 2020-09-30 | −$1.0M | −$656,984 | — |
| Q2 2020 | 2020-06-30 | −$659,109 | −$279,634 | — |
| Q1 2020 | 2020-03-31 | −$585,923 | −$224,103 | — |
| Q4 2019 | 2019-12-31 | −$634,366 | −$423,483 | — |
| Q3 2019 | 2019-09-30 | −$363,736 | −$686,769 | — |
| Q2 2019 | 2019-06-30 | −$379,475 | −$939,355 | — |
| Q1 2019 | 2019-03-31 | −$361,820 | −$1.3M | — |
| Q4 2018 | 2018-12-31 | −$210,883 | −$1.4M | — |
| Q3 2018 | 2018-09-30 | $323,033 | −$1.4M | −80.80% |
| Q2 2018 | 2018-06-30 | $559,880 | −$1.3M | −70.17% |
| Q1 2018 | 2018-03-31 | $964,898 | −$1.2M | −55.67% |
| Q4 2017 | 2017-12-31 | $1.2M | −$1.3M | −50.78% |
| Q3 2017 | 2017-09-30 | $1.7M | −$1.3M | −42.73% |
| Q2 2017 | 2017-06-30 | $1.9M | −$1.3M | −41.10% |
| Q1 2017 | 2017-03-31 | $2.2M | −$839,758 | −27.84% |
| Q4 2016 | 2016-12-31 | $2.5M | $3.1M | — |
| Q3 2016 | 2016-09-30 | $2.9M | $3.6M | — |
| Q2 2016 | 2016-06-30 | $3.2M | $3.7M | — |
| Q1 2016 · Mar 31 | 2016-03-31 | $3.0M | $3.4M | — |
| Q4 2015 · Dec 31 | 2015-12-31 | −$667,216 | −$401,216 | — |
| Q1 2016 · Sep 30 | 2015-09-30 | −$628,000 | −$495,000 | — |
| Q4 2015 · Jun 30 | 2015-06-30 | −$497,000 | −$476,000 | — |
| Q3 2015 | 2015-03-31 | −$385,000 | — | — |
| Q2 2015 | 2014-12-31 | −$266,000 | — | — |
| Q1 2015 | 2014-09-30 | −$133,000 | — | — |
| Q4 2014 | 2014-06-30 | −$21,000 | — | — |
| As of Sep 30, 2011 | 2011-09-30 | −$5.7M | — | — |
| As of Jun 30, 2011 | 2011-06-30 | −$1.1M | — | — |
Protagenic Therapeutics, Inc.\new shareholders’ equity trends
Between the periods ended 2014-06-30 and 2026-03-31, Protagenic Therapeutics, Inc.\new's shareholders’ equity increased from −$21,000 to $2.6M, a change of $2.6M. The latest reported quarter, Q1 2027, shows $1.7M.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Protagenic Therapeutics, Inc.\new source filings ↗